Singapore markets closed

Fulcrum Therapeutics, Inc. (FULC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.080.00 (0.00%)
As of 11:12AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 440.05M
Enterprise value 214.65M
Trailing P/E 315.25
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)154.75
Price/book (mrq)1.87
Enterprise value/revenue 76.52
Enterprise value/EBITDA -1.98

Trading information

Stock price history

Beta (5Y monthly) 2.28
52-week change 3156.52%
S&P500 52-week change 324.19%
52-week high 313.70
52-week low 32.62
50-day moving average 39.26
200-day moving average 36.18

Share statistics

Avg vol (3-month) 3637.49k
Avg vol (10-day) 3449.61k
Shares outstanding 562.15M
Implied shares outstanding 662.68M
Float 838.55M
% held by insiders 11.38%
% held by institutions 199.09%
Shares short (15 Apr 2024) 42.53M
Short ratio (15 Apr 2024) 44.35
Short % of float (15 Apr 2024) 45.08%
Short % of shares outstanding (15 Apr 2024) 44.08%
Shares short (prior month 15 Mar 2024) 42.39M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-3,213.78%

Management effectiveness

Return on assets (ttm)-28.56%
Return on equity (ttm)-44.84%

Income statement

Revenue (ttm)2.81M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)27.20%
Gross profit (ttm)N/A
EBITDA -108.49M
Net income avi to common (ttm)-97.33M
Diluted EPS (ttm)-1.59
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)236.22M
Total cash per share (mrq)3.81
Total debt (mrq)10.82M
Total debt/equity (mrq)4.60%
Current ratio (mrq)17.71
Book value per share (mrq)3.80

Cash flow statement

Operating cash flow (ttm)-90.97M
Levered free cash flow (ttm)-56.72M